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Hypertension has become the single leading cause of global disease burden ahead of smoking and alcohol use.1 All 
cardiovascular complications of hypertension are related to 
poor blood pressure (BP) control.2–4 Despite the widespread 
availability of effective antihypertensive therapies, BP control 
is achieved only in approximately half of the Western popu-
lations.5,6 One of the potential explanations for this apparent 
paradox is the pandemic of nonadherence to antihypertensive 
medications.7–10 Recent studies show that 25% to 65% hyper-
tensive patients do not take their BP-lowering medications as 
prescribed.8,10–18 These figures are extremely robust because 
they come from studies that used a direct and objective method 
of screening for therapeutic nonadherence.8,10–18 High perfor-
mance liquid chromatography–tandem mass spectrometry 
(LC-MS/MS) provides a highly sensitive and specific detec-
tion of all commonly prescribed BP-lowering medications (or 
their metabolites) in urine/serum samples. Because of its sim-
plicity, relatively low cost, and objective nature of analysis, it 
is a useful diagnostic test in patients with apparent lack of BP 
response to antihypertensive treatment.17
Here, we examined the potential therapeutic applications 
of biochemical screening for the presence of antihypertensive 
medications in bodily fluids. We demonstrate that nonadherent 
patients who undergo LC-MS/MS–based analyses exhibit an 
Abstract—We hypothesized that screening for nonadherence to antihypertensive treatment using liquid chromatography-
tandem mass spectrometry–based biochemical analysis of urine/serum has therapeutic applications in nonadherent 
hypertensive patients. A retrospective analysis of hypertensive patients attending specialist tertiary care centers was 
conducted in 2 European countries (United Kingdom and Czech Republic). Nonadherence to antihypertensive treatment 
was diagnosed using biochemical analysis of urine (United Kingdom) or serum (Czech Republic). These results 
were subsequently discussed with each patient, and data on follow-up clinic blood pressure (BP) measurements were 
collected from clinical files. Of 238 UK patients who underwent biochemical urine analysis, 73 were nonadherent to 
antihypertensive treatment. Their initial urinary adherence ratio (the ratio of detected to prescribed antihypertensive 
medications) increased from 0.33 (0–0.67) to 1 (0.67–1) between the first and the last clinic appointments. The observed 
increase in the urinary adherence ratio in initially nonadherent UK patients was associated with the improved BP control; 
by the last clinic appointment, systolic and diastolic BPs were ≈19.5 and 7.5 mm Hg lower than at baseline (P=0.001 
and 0.009, respectively). These findings were further corroborated in 93 nonadherent hypertensive patients from Czech 
Republic—their average systolic and diastolic BPs dropped by ≈32.6 and 17.4 mm Hg, respectively (P<0.001), on 
appointments after the biochemical analysis. Our data show that nonadherent hypertensive patients respond to liquid 
chromatography–tandem mass spectrometry-based biochemical analysis with improved adherence and significant BP 
drop. Such repeated biochemical analyses should be considered as a therapeutic approach in nonadherent hypertensive 
patients.  (Hypertension. 2017;70:1042-1048. DOI: 10.1161/HYPERTENSIONAHA.117.09631.)
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improvement in adherence and a clinically meaningful BP drop. 
We further show that a majority of initially nonadherent patients 
can successfully improve their adherence through repeated 
LC-MS/MS–based analysis and achieve BP targets similar to 
those who have been persistently adherent to treatment.
Methods
Data Collection and Biochemistry
UK Patients
We collected retrospective data from patients attending University 
Hospitals of Leicester NHS Trust Blood Pressure Clinic (European 
Society of Hypertension Centre of Excellence) between 2011 and 
2014. Included in this analysis were hypertensive patients who had at 
least 1 biochemical screening for nonadherence to antihypertensive 
treatment (by LC-MS/MS of urine) during this period. Referred for the 
biochemical screening for nonadherence in the UK center were patients 
suspected to deviate from the prescribed antihypertensive therapy by 
their managing doctor as reported before.19 None of the patients asked 
to provide a urine sample for LC-MS/MS–based analysis refused to 
undertake the test. Apart from the results of LC-MS/MS–based urine 
analyses, we collected available basic demographic and clinical charac-
teristics, information on prescribed antihypertensive medications, and 
their changes between the first (baseline) and the last clinical appoint-
ments (as defined by the timing of LC-MS/MS–based urine analy-
sis). BP was recorded using a validated semiautomatic device (A&D 
Digital BP Monitor UA-767PC, A&D Instruments, Abingdon, United 
Kingdom). Measurements were made as per the National Institute of 
Health and Care Excellence Guideline 127.20 The 24-hour ambulatory 
BP monitoring was conducted using Spacelabs 90217A-1 monitors 
(Space Labs Healthcare, Snoqualmie, Washington) in line with the 
National Institute of Health and Care Excellence guidelines.20
On the day of their clinic appointment, patients were asked to 
provide a urine sample for the analysis of their adherence to anti-
hypertensive medications.10 Briefly, the LC-MS/MS–based screening 
detects 40 of the most commonly prescribed antihypertensive medi-
cations.10 Samples were collected in a standard container, stored at 
−80°C until analysis, and examined using the Agilent Technologies 
1290 High Pressure Liquid Chromatograph interfaced with an 
Agilent Technologies 6460 Triple Quad Mass Spectrometer (Santa 
Clara, CA) fitted with a jet stream electrospray source. The detection 
was based on the presence of the specific precursor ion to product ion 
transition (at least 2 for each analyte) and retention times.10
Patients whose baseline urine analysis by LC-MS/MS did not de-
tect at least one of the prescribed antihypertensive medications were 
classified as initially nonadherent. Those whose baseline urine analy-
sis detected all prescribed antihypertensive medications were clas-
sified as initially adherent. Patients who were initially nonadherent 
as defined above but whose subsequent urine analysis detected all 
prescribed medications were defined as converters. Patients who were 
initially adherent as defined above and whose subsequent urine analy-
sis continued to show presence of all prescribed medications were 
classified as persistently adherent.
Czech Republic Patients
All hypertensive patients referred with suboptimal BP control to 
the Hypertension Unit at the 3rd Department of Medicine, General 
University Hospital, in Prague between 2010 and 2016 were included 
in the initial retrospective analysis of clinical notes. Included in this 
project were hypertensive patients diagnosed with nonadherence 
to antihypertensive treatment by LC-MS/MS–based analysis and at 
least 2 clinic appointments with recorded clinic BP values. The Czech 
patients were referred for LC-MS/MS–based analysis if their treat-
ing clinician found their BP control was suboptimal on the existing 
antihypertensive treatment.20 None of the patients asked to provide a 
blood sample for LC-MS/MS–based analysis refused. Similar to the 
UK cohort, information on demographic data, prescribed antihyper-
tensives, and clinic BP values recorded at baseline and on follow-up 
appointments was retrieved retrospectively from the clinical files or 
electronic systems. The follow-up appointments were conducted either 
in Hypertension Unit at the 3rd Department of Medicine, General 
University Hospital, in Prague or in the primary care. BP measure-
ments were taken using validated oscillometric automated devices in 
line with guidelines of the Czech Society of Hypertension.21
Serum samples were collected on the initial visit in the outpatient 
clinic of the Hypertension Unit. Analysis of the serum concentra-
tions of antihypertensive medications was performed as described 
before.22–25 Serum samples were collected as a part of routine ser-
vice and sent to the Toxicology laboratory of the Institute of Forensic 
Medicine and Toxicology. The samples were aliquoted and stored at 
−80°C until analysis. The LC-MS/MS was performed using Agilent 
Technologies 1200 Rapid Resolution Liquid Chromatography con-
sisting of a degasser, binary pump, autosampler, and thermostatted 
column compartment. The mass spectrometry analysis was per-
formed using an MDS Sciex 3200 Q142 trap triple quadrupole/linear 
ion trap mass spectrometer with a TurboIonSpray source.
Patients whose baseline serum analysis by LC-MS/MS did not de-
tect at least one of the prescribed antihypertensive medications were 
classified as nonadherent.
The studies comply with the Declaration of Helsinki. In the UK 
cohort, patients were informed about the purpose of urine collec-
tion on the day of their clinical appointment. The UK patients gave a 
verbal consent for the biochemical screening for nonadherence, and 
the project was approved by University Hospitals of Leicester (audit 
registration number: 5944) and ratified by the local ethics commit-
tee (reference no: 17/EM/0027). Czech Republic patients provided a 
written consent for collection of their data in anonymized form, and 
the project received an institutional approval (VFN 004707/2017). 
The results of all biochemical analyses were sent to the appropri-
ate clinician who informed the patients of the findings and discussed 
them during their clinic appointment. The form and timing of the dis-
cussion were left to the discretion of the responsible clinician.
Statistical Analysis
Descriptive statistics are presented as counts (percentages), means 
(SDs), or medians (interquartile ranges). Crude comparisons of basic 
demographic and clinical characteristics between 2 groups (ie, ini-
tially adherent versus nonadherent patients) were conducted using 
Fisher exact test or t test as appropriate. The groups were also com-
pared in terms of the number of prescribed and detected BP-lowering 
drugs, adherence ratio, and BP over follow-up appointments using 
mixed-effects regression models to account for the correlated nature 
of observations across the appointments. Continuous variables, such 
as BP, were log transformed, the adherence proportion data were arc-
sine transformed, and both analyzed using linear mixed-effects mod-
els. Variables based on counts, such as the differences in the number 
of prescribed and detected antihypertensive medications, were exam-
ined using Poisson mixed-effects models. Nondemographic compari-
sons were adjusted for age, sex, ethnicity (where appropriate), and the 
number of prescribed antihypertensive medications. The R2 of mixed-
models was evaluated using Nakagawa and Schielzeth’s approach.26 
All analyses were conducted using R27 with the use of the following 
R packages: lme4,28 data.table,29 and ggplot2.30
Results
General Clinical Characteristics
Of 238 UK patients included in this analysis, 165 and 73 were 
classified as initially adherent and nonadherent (respectively) 
based on the results of their first LC-MS/MS urine test. The 
basic demographic characteristics, as well as the percentage of 
attended follow-up appointments, were similar in both groups 
(Table 1). The clinical characteristics of 93 Czech patients 
whose nonadherence was confirmed by LC-MS/MS–based 
analysis of serum are also shown in Table 1. None of the UK 
or Czech patients with the initial biochemical confirmation of 
nonadherence to antihypertensive treatment admitted being 
nonadherent before the LC-MS/MS–based analysis.
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Initially Nonadherent Hypertensive Patients 
Show Steeper Reduction in BP on Follow-Up 
Appointments Than Those Who Are Initially 
Adherent to Antihypertensive Therapy
As expected, on the first clinic appointment, initially nonadherent 
patients had higher BP values than those who adhered to antihy-
pertensive therapy (Table 2). However, there were no statistically 
significant differences in either clinic systolic BP (SBP) or dia-
stolic BP (DBP) between both groups on the last clinic appoint-
ment (Table 2). This pattern of changes was replicated for both 
mean SBP and DBP on 24-hour ambulatory BP monitoring 
(Table 2). The median number of prescribed antihypertensive 
medications increased from 2 to 3 in the initially adherent group 
but remained constant at 4 in the initially nonadherent patients 
Table 1. Demographic and Clinical Characteristics of Patients
Characteristic
United Kingdom Czech Republic
All Initially Adherent Initially Nonadherent P Value Initially Nonadherent
n 238 165 73 … 93
Age, y 54.3 (16.3) 53.3 (17.8) 56.6 (12.1) 0.094 51.4 (10.5)
Female sex (%) 128 (53.8) 84 (50.9) 44 (60.3) 0.206 53 (57)
White ethnicity (%) 151 (63.4) 113 (68.5) 38 (52.1) 0.019 93 (100)
Attendance at the second clinic appointment (%) 214 (89.9) 149 (90.3) 65 (89.0) 0.817 …
Attendance at the last clinic appointment (%) 166 (69.7) 112 (67.9) 54 (74.0) 0.364 93 (100)
Time between first and second appointments, mo 4.5 (3.1) 4.5 (3.3) 4.5 (2.7) 0.977 …
Time between second and last appointments, mo 10.9 (7.0) 9.8 (6.3) 13.4 (7.8) 0.003 …
Data are means (SDs) or counts (percentages). P value indicates level of statistical significance for the difference between initially adherent and 
nonadherent patients from United Kingdom.
Table 2. Blood Pressure Values on Follow-Up Appointments: Comparison of Initially Adherent and 
Initially Nonadherent Patients
Clinic Appointment Initially Adherent Initially Nonadherent P Value
 n Clinic SBP, mm Hg n Clinic SBP, mm Hg  
First 152 [13] 154.5 (21.7) 69 [4] 167.8 (21.5) <0.001
Second 126 [23] 143.8 (19.7) 61 [4] 158.9 (27.8) <0.001
Last 90 [22] 140.5 (17.9) 50 [4] 147.1 (23.1) 0.247
  Clinic DBP, mm Hg  Clinic DBP, mm Hg  
First 152 [13] 88.7 (14.0) 69 [4] 94.8 (12.8) <0.001
Second 126 [23] 86.0 (14.9) 61 [4] 89.6 (17.7) 0.012
Last 90 [22] 82.9 (13.8) 50 [4] 84.4 (14.6) 0.187
  24-h mean SBP, mm Hg  24-h mean SBP, mm Hg  
First 109 [56] 147.5 (14.9) 37 [36] 156.8 (18.9) 0.037
Second 26 [123] 151.2 (24.1) 11 [54] 156.1 (22.3) 0.667
Last 15 [97] 136.9 (14.8) 7 [47] 149.3 (14.6) 0.198
  24-h mean DBP, mm Hg  24-h mean DBP, mm Hg  
First 109 [56] 86.4 (12.2) 37 [36] 90.3 (12.3) 0.012
Second 26 [123] 84.2 (13.5) 11 [54] 86.8 (12.6) 0.130
Last 15 [97] 78.1 (14.2) 7 [47] 82.1 (8.6) 0.134
  Medications  Medications  
First 165 [0] 2 (1–4) 73 [0] 4 (3–5) <0.001
Second 148 [1] 3 (2–4) 65 [0] 4 (3–5) 0.003
Last 111 [1] 3 (2–4) 54 [0] 4 (3–5) 0.042
Data are counts (percentages), medians (interquartile ranges), or means (SDs). n indicates number of patients with available 
data [number of patients with missing data]; medications, number of prescribed antihypertensive medications; P value, level of 
statistical significance for the difference between initially adherent and initially nonadherent patients adjusted for age, sex, and 
ethnicity; blood pressure comparisons were also adjusted for the number of prescribed medications. DBP indicates diastolic blood 
pressure; and SBP, systolic blood pressure.
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(Table 2). Further sensitivity analyses restricted to those with 
suboptimal BP control on treatment with at least 3 antihyper-
tensive medications (including a diuretic)31 confirmed that the 
differences in BP between initially nonadherent and adherent 
patients followed the pattern of changes observed in the analysis 
of the entire cohort of hypertensives (data not shown).
LC-MS/MS–Based Analysis Is Associated With 
Better Adherence to Antihypertensive Treatment 
and Improved BP Control in Initially Nonadherent 
Patients
We further examined the patterns of changes in adherence to 
antihypertensive therapy and BP exclusively in UK patients who 
were nonadherent on their first clinic appointment. Of 73 ini-
tially nonadherent patients, 30 had repeated LC-MS/MS–based 
urine analysis coinciding with clinic BP measurements. There 
were no statistically significant differences in their basic clinical 
characteristics when compared with the 43 nonadherent patients 
who did not have repeated urine analysis (data not shown). The 
median adherence ratio increased between their first and last 
appointments (Table 3). Although the median number of pre-
scribed medications remained constant (P=0.906), the median 
number of drugs detected in urine by LC-MS/MS increased 
from 1 to 3 (P<0.001; Table 3). By the last appointment, 80% 
of the 30 initially nonadherent patients with follow-up LC-MS/
MS–based analysis improved their urinary adherence ratio and 
53.3% became fully adherent (converters). We also recorded 
19.5- and 7.5-mm Hg reduction in SBP and DBP (respectively) 
between the patients’ first and last appointments (Table 3).
An additional analysis conducted in an independent sample 
of 93 nonadherent hypertensive patients from Czech Republic 
revealed even more significant reduction in BP—average 
SBP and DBP dropped by 32.6 and 17.4 mm Hg, respectively 
(P<0.001) on appointments after the initial LC-MS/MS–based 
serum analysis. This BP reduction occurred without statisti-
cally significant changes in the average number of prescribed 
antihypertensive medications (Table 3).
Initially Nonadherent Patients Who Become 
Converters Reach BP Similar to That of Persistently 
Adherent Patients
Nineteen initially adherent patients had repeated LC-MS/MS–
based urine analysis and remained adherent to treatment by 
the final clinic appointment (persistently adherent patients). 
Their clinical characteristics are shown in Table 4. Although 
the baseline clinic BP was numerically lower in persistently 
adherent patients than in converters, by the last appointment, 
both clinic SBP and DBP became statistically comparable 
between both groups of patients (Table 4).
Numeric Change in the Adherence Ratio Shows 
a Correlation With the Drop in BP in Initially 
Nonadherent Patients Who Underwent Repeated 
Urine Analysis and BP Measurements
We detected a significant association between the increase in 
the adherence ratio (on LC-MS/MS–based urine analysis) and 
drop in BP (on clinic measurements) in 29 UK patients who 
underwent repeated screening for nonadherence and had BP 
measurements taken on the same visits (R2=0.25, P=0.002 for 
SBP and R2=0.21, P=0.005 for DBP). An average increase in 
urinary adherence ratio of 0.5 correlated with an ≈16-mm Hg 
drop in SBP and 9-mm Hg drop in DBP (Figure). After adjust-
ment for age, sex, ethnicity, and the number of prescribed 
drugs, the association between the increase in the urinary 
adherence ratio and drop in BP remained significant (P=0.010 
for SBP and P=0.006 for DBP)
Discussion
Our study provides several important insights into the poten-
tial therapeutic use of biochemical screening for nonadher-
ence to antihypertensive treatment. First, we demonstrate that 
nonadherent hypertensive patients who underwent LC-MS/
MS–based analysis of urine/serum and were informed of the 
results exhibit a significant BP drop on subsequent clinical 
appointments. Second, we show that repeated LC-MS/MS–
based analyses have the potential to normalize adherence to 
antihypertensive treatment in a majority of initially nonadher-
ent patients. Third, our data suggest that the observed improve-
ment in BP on follow-up appointments can be explained by 
an improvement in urinary adherence ratio. Finally, we reveal 
that those who fully convert from initial nonadherence to full 
adherence may achieve BP levels similar to those who have 
been persistently adherent to treatment.
We and others previously demonstrated the diagnostic 
use of LC-MS/MS–based screening in detecting nonadher-
ence to antihypertensive treatment.8,10–12,14–18 It also emerges 
Table 3. Changes in Clinic Blood Pressure and Adherence to Antihypertensive Treatment in Initially Nonadherent Patients
United Kingdom Czech Republic
Characteristics
First 
Appointment
Second 
Appointment
Last 
Appointment P Value
First 
Appointment
Last 
Appointment P Value
n 73 23 17 … 93 93 …
Adherence ratio 0.33 (0–0.67) 0.60 (0.13–1) 1 (0.67–1) <0.001 0.17 (0–0.50) … …
No. of drugs prescribed 4 (3–5) 4 (4–5) 4 (3–5) 0.906 4 (3–4) 4 (3–5) 0.436
No. of drugs detected 1 (0–2) 3 (0.5–4) 3 (2–4) <0.001 1 (0–2) … …
SBP, mm Hg 167.8 (21.5) 162.7 (28.8) 148.3 (24.5) 0.001 183.6 (25.8) 151.0 (27.8) <0.001
DBP, mm Hg 94.8 (12.8) 93.8 (20.0) 87.3 (13.4) 0.009 108.3 (14.9) 90.9 (14.6) <0.001
Data are counts, medians (interquartile ranges) or means (SDs). Adherence ratio, the urinary ratio of detected to prescribed antihypertensive medications; 
P value, level of statistical significance for comparison of the first and last appointments adjusted for age and sex; blood pressure comparisons were also 
adjusted for the number of prescribed medications. DBP indicates diastolic blood pressure; and SBP, systolic blood pressure.
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that biochemical screening for nonadherence to BP-lowering 
therapy may be helpful in treatment of hypertension. Indeed, 
16 hypertensive patients with biochemically confirmed non-
adherence showed 46- and 14-mm Hg drop in clinic SBP 
and DBP, respectively, on follow-up in a pilot US study.13 
We extend these observations to larger samples of patients 
recruited in 2 European countries. Most importantly, our study 
demonstrates that a reduction in BP can be explained (at least 
in part) through improved therapeutic adherence (as measured 
by the average increase in detected BP-lowering medications 
and the absolute increase in urinary adherence ratio).
We also show for the first time that as the directly measured 
adherence ratio improves over the follow-up appointments, the 
number of initially nonadherent patients drops, and adher-
ence normalizes in 53.3% of initially nonadherent individuals. 
This means that a majority of initially nonadherent patients 
may convert into adherence on repeated LC-MS/MS–based 
analysis. The mechanisms responsible for BP reduction after 
LC-MS/MS–based analyses remain unclear. We anticipate that 
discussing the results of LC-MS/MS–based analysis break 
down key barriers to adherence on both the clinician’s and the 
patient’s side.32,33 In our study, the form and content of this dis-
cussion were left at the discretion of the managing physician. 
At University Hospitals of Leicester BP clinic, this structured 
discussion aims to identify and eliminate the lead reason(s) 
for nonadherence to antihypertensive treatment. The concep-
tual principles of this intervention are rooted in the apparent 
BP-lowering efficacy of therapeutic drug monitoring13 and 
follow the strategy proposed by National Institute of Clinical 
Excellence (National Institute for Health and Care Excellence) 
guidelines on adherence to medicines.34 The discussion focuses 
primarily on (1) polypharmacy, (2) practical difficulties (ie, 
forgetting, managing treatment costs, etc.) that through limita-
tions in capability and resources affect ability to adhere, and 
(3) perceptions affecting the motivation to adhere (eg, beliefs 
that daily treatment is not necessary and concerns about harm). 
Such structured discussions are intended to help clinicians to 
explain the results of the urine analysis with the patients and 
to tailor adherence support through addressing the specific 
perceptual and practical factors influencing the patients’ moti-
vation and ability to adhere as recommended in the National 
Institute for Health and Care Excellence Guidelines.34
Table 4. Clinical Characteristics, Adherence to 
Antihypertensive Treatment, and Clinic Blood Pressure in 
Converters and Persistently Adherent Patients
Characteristic
Clinic 
Appointment Converters
Persistently 
Adherent P Value
n … 16 19 …
Age, y … 54.6 (13.7) 64.4 (15.3) 0.052
Female sex (%) … 12 (75) 11 (58) 0.476
White ethnicity (%) … 9 (56) 13 (68) 0.503
No. of drugs 
prescribed
First 4 (3.5–5) 4 (2–4.5) 0.066
Second 4 (3.5–5) 3 (2–4) 0.069
Last 4 (3.5–5) 3.5 (3–4) 0.178
SBP, mm Hg First 174.4 (17.8) 157.8 (25.2) 0.004
Second 156.6 (27.3) 157.2 (24.4) 0.800
Last 138.4 (19.0) 148.6 (17.3) 0.342
DBP, mm Hg First 96.1 (17.4) 81.8 (16.7) 0.074
Second 90.9 (22.3) 85.8 (17.7) 0.906
Last 84.2 (16.4) 86.1 (11.2) 0.143
Data are counts (percentages), medians (interquartile ranges), or means (SDs). 
Converters, initially nonadherent patients who by their last clinic appointment 
converted to fully adherent; persistently adherent, initially adherent patients 
who remained fully adherent on repeated testing; P value, level of statistical 
significance for comparison between converters and persistent adherers; 
comparisons at each appointment were adjusted for age, sex, and ethnicity; 
blood pressure comparisons were also adjusted for the number of prescribed 
drugs. DBP indicates diastolic blood pressure; and SBP, systolic blood pressure.
Figure. Association between changes in 
blood pressure and urinary adherence 
ratio in initially nonadherent patients. 
X axis represents the change in urinary 
adherence ratio (the ratio of detected to 
prescribed antihypertensive medications), 
y axis represents the change in clinic 
blood pressure (BP; mm Hg), data points 
are changes in BP and urinary adherence 
ratio between the appointments with 
complete information (both BP and 
adherence) available, P value indicates 
level of statistical significance for 
association between the change in 
urinary adherence ratio and change in 
systolic BP (SBP) and diastolic BP (DBP).
 by guest on O
ctober 24, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
Gupta et al  Biochemical Nonadherence Screening Improves BP  1047
The potential benefits of LC-MS/MS–based analysis 
in managing nonadherent hypertensive patients should not 
be underestimated. First, a reduction of ≈20 mm Hg in SBP 
achieved by repeated biochemical analysis may potentially 
translate into a 45% reduction in risk of coronary heart dis-
ease and ≈65% reduction in risk of stroke.4,35 Conversion of 
the majority of nonadherent hypertensive patients to adherence 
with a significant drop in BP would be an important break-
through in the field, given that previous studies showed lim-
ited benefits from complex and costly interventions.36–38 Based 
on the previous simulations, 54% improvement in adherence 
(conversion from nonadherence to adherence) at the population 
level may reduce the number of strokes, myocardial infarction, 
kidney disease, and heart failure by ≈4.6 million with a cost 
reduction of ≈$39 billion.39 In economic terms, nonadherence 
to antihypertensive medications accounts for ≈$18.5 billion 
excess costs to the US health economy.40 Thus, the change of 
more than half of nonadherent patients to adherence patients 
with improvement of their BP control by ≈20 mm Hg is likely 
to have an important impact on health economy if the tests were 
used routinely and on a widespread basis. It is worth reflect-
ing that the cost of the assay is less than a monthly supply of 
antihypertensive medications for some patients. Further larger, 
prospective randomized controlled trials are necessary to pre-
cisely quantify the efficacy of LC-MS/MS–based intervention 
and elucidate the factors behind the successful conversion from 
nonadherence to adherence to antihypertensive treatment.
We appreciate some limitations of our study. First, the 
patients who underwent this analysis represent a specific 
group of hypertensive patients with suboptimal BP control. 
Second, our results are based on retrospective analyses of clin-
ical notes, and we recognize the limitation of incomplete data 
availability and unmeasured confounding inherent to this type 
of analysis. Third, information on the reasons for nonadher-
ence was not formally a part of our data collection. However, 
forgetfulness emerges as one of the most common drivers of 
suboptimal adherence in interviews with patients conducted at 
University Hospitals of Leicester BP clinic. This form of non-
intentional nonadherence to antihypertensive therapy was also 
demonstrated as one of the main barriers to adherence in other 
studies.41,42
 Our study is not immune from the so-called tooth-
brush effect43—patients may have taken their medications just 
before their clinic appointment and thus influence their clinic 
BP measurement. To this end, the availability of 24-hour 
ambulatory BP monitoring data showing the same direction of 
BP changes is reassuring because this investigation was con-
ducted at a different time point from the clinic appointment. 
Finally, our data provide insights into repeated snapshots of 
adherence rather than continuous therapeutic persistence.
Perspectives
We show that repeated biochemical screening for nonadher-
ence by LC-MS/MS is associated with BP reduction. We 
further demonstrate that a majority of nonadherent patients 
can be converted to full adherence by repeated testing with 
optimization of their BP control. To this end, we suggest that 
repeated LC-MS/MS–based analysis should be considered as 
a potential therapeutic approach to nonadherence-driven pseu-
doresistant hypertension. Future well-designed studies are 
needed to confirm these findings in prospective clinical trials 
and address the impact of this test on cardiovascular outcomes 
and its impact on the global health economy.
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What Is New?
•	Hypertensive patients with biochemically confirmed nonadherence to an-
tihypertensive treatment respond to the liquid chromatography-tandem 
mass spectrometry analysis with a significant drop in blood pressure.
•	 Eighty percent of initially nonadherent hypertensive patients show an im-
provement in their adherence in response to initial biochemical screening.
What Is Relevant?
•	Biochemical testing for nonadherence has an important therapeutic po-
tential.
Summary
Biochemical screening for nonadherence to antihypertensive treat-
ment leads to a significant improvement in blood pressure as a 
result of improved adherence.
Novelty and Significance
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